Already a member? Login here
By creating an account you agree to our Terms and Conditions, Terms of Use, and Privacy Policy and you understand that by downloading vendor information you are agreeing to share your contact information with that vendor.
Now more than ever, drug developers need an experienced global partner to advance Companion Diagnostic (CDx), development, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success. CDx enables more effective development of personalized medicine by identifying likely patient responders based on efficacy and safety. With an extensive instrument footprint in laboratories throughout the world, Q2 Solutions® can expediently service CDx requests utilizing a range of technologies: immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) next generation sequencing (NGS), and quantitative polymerase chain reaction (PCR).
Q2 Solutions® has a venerable track record of successfully supporting drug developers and in-vitro diagnostic (IVD) companies in many global CDx programs, from the early stages of biomarker validation through clinical trials testing and commercialization.
Article: Elevating Effective Outcomes with Companion Diagnostics
Podcast: Companion Diagnostics: I-O clinical development podcast series
Webinar: Unlocking the Power of Genomic Research with IQVIA Bioinformatic Capabilities
Video: Global Anatomic Pathology Clinical Trial Lab Services
![The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology. [iStock/LilliDay]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/307-218x150.jpeg "AI Algorithm Could Reduce Breast Cancer Mammogram False Positive Rate")
